Abstract
Retinoblastoma (RB), the most common intraocular malignancy in children, was historically treated with definitive external beam radiation therapy (EBRT). Over the last 15 years, chemoreduction with intensive focal therapy has been shown to achieve excellent control while avoiding radiation-induced morbidity and mortality (due to secondary malignancy). However in the setting of residual disease after enucleation or diffuse vitreous or subretinal seeding, EBRT still plays an important role. We evaluated our institutional long term outcomes for advanced stage RB in the setting of modern treatment techniques.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
